Can a One-Time gene shot calm inflammation in ALS?

NCT ID NCT06704347

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a single injection of XT-150, a gene therapy that produces an anti-inflammatory protein, is safe for people with ALS. Eight adults with ALS will receive one of two doses and be followed for six months. The goal is to check for side effects and see how the body processes the therapy, not yet to measure whether it slows the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single injection of XT-150, a piece of DNA that produces an anti-inflammatory protein called interleukin-10
What this could lead to
If safe, this could pave the way for a new approach to slow nerve damage in ALS by reducing inflammation in the nervous system.
What could go wrong
This is a very early, small safety study with only 8 participants, so it cannot prove whether the treatment works. Gene therapies can also cause unexpected immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barrow Neurological Institute (St. Joseph's)

    Phoenix, Arizona, 85013, United States

  • Henry Ford Health

    Detroit, Michigan, 48202, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21205, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.